6 / 32
ASPIRATION study
« PFS1 »
« PFS2 »
Parck JAMA Oncol 16
Erlotinib beyond RECIST PD improved 3.9 mo. the PFS
(from 11 mo. to 14.9 mo.) for tumours with common
EGFR
mutant
|
|
6 / 32
6 / 32
ASPIRATION study
« PFS1 »
« PFS2 »
Parck JAMA Oncol 16
Erlotinib beyond RECIST PD improved 3.9 mo. the PFS
(from 11 mo. to 14.9 mo.) for tumours with common
EGFR
mutant